The S&P 500 (SNPINDEX:^GSPC) set its latest record close, 7,818.93, on Oct. 6. As of this writing, it’s just a little over 1% under that mark. For anyone with a lot of cash meant for an index fund, putting it all in so close to a record can seem like asking for bad timing. The

Your parents’ nest egg was mostly bonds and savings accounts. Yours is mostly stocks. Stocks made up 48.2% of Americans’ financial assets in the second quarter, counting everything from brokerage accounts to 401(k)s, according to the Federal Reserve’s latest Financial Accounts data. That’s the highest share in records going back to 1945. It tops the

Applied Materials Sinks 17% in a Week After a Forecast-Free Investor Day: “Tremendous Confidence” ©@Kittipong Jirasukhanont from PhonlamaiPhoto’s Images via Canva, @Iulian Catalin’s Images via Canva Key Takeaways Applied Materials stock has declined 24% since October 12, including a 6.7% drop following its October 13 investor presentation. Management outlined ambitious 2030 profitability targets but declined

The S&P 500 (SNPINDEX:^GSPC) and Nasdaq Composite (NASDAQINDEX:^IXIC) have added 12% in 2026 despite a number of economic headwinds. That puts both indexes on pace for their fourth consecutive year of double-digit gains for the first time since the late 1990s. However, investors recently got bad news about the economy. Inflation accelerated in September, as

Palantir (NASDAQ: PLTR) investors have had a fairly rocky 2026. For most of the year, the stock was losing money. However, starting in August, Palantir reversed the decline and has now gained about 12% for the year. That is roughly in line with the gain for the S&P 500 (SNPINDEX: ^GSPC). However, if you survey

3 Reasons to sell NEOG and 1 stock to buy instead Neogen’s 25.9% return over the past six months has outpaced the S&P 500 by 16.8%, and its stock price has climbed to $11.78 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Oil just hit a five month high as supply risks from the Middle East and attacks on key energy facilities push energy markets back into the spotlight. When crude prices get this much attention, the largest integrated producers and pipeline giants can draw fresh investor interest. This article walks through three leading global oil and

The AI trade has looked awfully shaky over the last couple of weeks. CoreWeave, the neocloud company that may have more leveraged exposure to AI than any other company due to its massive debt burden, has plunged in recent weeks on fears over its rising debt yields. Missed AI’s “Act 1”? Act 2 Could Be

Hormel Foods has seen its share price slide over the past few years, and that drop puts a spotlight on a simple question for investors who focus on fundamentals. Is the current valuation of Hormel stock still in line with the earnings power the business is producing today? Over the past 5 years, the share

Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for the next breakthrough.

Space Exploration Technologies (NASDAQ: SPCX) reported its third-quarter earnings after the market closed on Tuesday, Oct. 20. Ahead of the report, I laid out what I’d be looking for. And, frankly, the latest report was better than I expected in several key ways. Here’s a look at what the company’s Q3 earnings showed. Missed AI’s

Shares of AT&T (NYSE:T) fell 8% on Friday after a new report stoked investors’ fears of a potentially disruptive encroachment by Space Exploration Technologies (NASDAQ:SPCX) into the lucrative U.S. wireless market. Image source: Getty Images. Missed AI’s “Act 1”? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they

Black said Tesla must divulge data on how many customers keep their full self-driving (FSD) subscriptions 3-6 months after the free trial of the technology ends. The comment comes on the heels of Tesla confirming earlier this week that over 75% of deliveries in North America in the third quarter included a sign-up for a

Kulicke and Soffa (KLIC): buy, sell, or hold post Q2 earnings? Over the past six months, Kulicke and Soffa’s stock price fell to $72.89. Shareholders have lost 13.9% of their capital, which is disappointing considering the S&P 500 has climbed by 9.1%. This may have investors wondering how to approach the situation. Is now the

Shares of RingCentral (NYSE:RNG) rose 5% on Friday after the communications software provider raised its full-year free cash flow forecast. Image source: Getty Images. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same

Robinhood (NASDAQ: HOOD) hasn’t announced any plans to launch single-stock perpetual futures on its platform yet, but there seems to be a lot of pent-up demand for them. In a recent Mizuho (NYSE: MFG) survey of over 600 active Robinhood users, 94% of respondents were willing to trade single-stock perpetual futures if they became available.

Two of the AI building boom’s biggest suppliers just posted blowout quarters. Wall Street is dumping them anyway. Bloom Energy (BE), whose fuel cells generate power on-site at data centers, said Thursday that sales jumped 138% last quarter and raised its full-year outlook to roughly 122% growth. Comfort Systems (FIX), which installs the cooling and

Bloom Energy (NYSE:BE) delivered another blowout quarter, smashing estimates and growing profits faster than sales. Yet, its stock plunged after earnings and was down more than 12% as of Friday noon. The company sells solid-oxide fuel cell servers that turn natural gas into electricity right at a customer’s site. Artificial intelligence (AI) data centers desperately

Moderna (MRNA) trimmed losses Friday, rebounding from a sharp sell-off in the previous session, as investors digested data from a late-stage trial of its personalized melanoma vaccine. The stock opened lower but climbed into positive territory during the session, a day after plunging more than 17% on Thursday in its worst single-day performance since Aug.